Carigent Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Carigent Therapeutics' novel nanoparticle targeted drug delivery technology allows for controlled release of therapeutic agents, targeting drugs to a particular physiological site, tethering of surface ligands, and the ability to combine multiple agents--like imaging agents and drugs--into one vehicle. The foundation of the platform is an FDA-approved biocompatible and biodegradable polymer material, PLGA, which is made into particles at the nano- or micro-scale depending on the application.